PathoGenetix Names Ann Merrifield as Chief Executive Officer and…

Experienced in developing high-growth biotechnology businesses, Merrifield will lead the commercialization of PathoGenetix’s proprietary Genome Sequence Scanning™ (GSS™) technology for application in...

(PRWeb December 05, 2012)

Read the full story at http://www.prweb.com/releases/pathogenetix/bacterial-identification/prweb10201022.htm

Comments are closed.